| 2001-12 |
Founded Kringle Pharma Inc. in Kita-ku, Osaka City. |
| 2001-12-21 |
Established Clingul Pharma Co., Ltd. as a drug discovery bio‑venture originating from Osaka University and Keio University. |
| 2005-05 |
Obtained development rights for HGF protein from the late Professor Toshio Nakamura (Professor Emeritus, Osaka University) and commenced development (development code: KP-100). |
| 2007-06 |
Established a manufacturing method for large-scale production of HGF protein active ingredient (pharmaceutical grade). |
| 2012-04 |
Completed a Phase Ib clinical trial of HGF protein in patients with renal failure in the United States. |
| 2015-03 |
Completed a Phase I clinical trial of HGF protein in ALS patients in Japan. |
| 2016-11 |
Completed a Phase I/II clinical trial (physician-led) of HGF protein in patients with vocal fold scarring in Japan. |
| 2018-10 |
Completed a Phase I/II clinical trial of HGF protein in acute spinal cord injury patients in Japan. |
| 2019-09 |
The Ministry of Health, Labour and Welfare designated HGF protein for acute spinal cord injury as a rare disease drug. |
| 2020-03 |
Capital and business alliance with Toho Holdings Inc. to establish a wholesale distribution system for HGF drug targeting acute spinal cord injury. |
| 2020-04 |
Signed a license and supply agreement with Clarus BioTherapeutics Inc. in the United States. |
| 2020-07 |
Initiated a Phase III clinical trial of KP-100IT in acute spinal cord injury patients in Japan. |
| 2020-08 |
Capital and business alliance with Maruishi Pharmaceutical Co., Ltd. to build a sales system for KP-100IT targeting acute spinal cord injury. |
| 2020-12 |
Listed shares on the Tokyo Stock Exchange Mothers market (now Growth market). |
| 2021-02 |
Signed a joint research agreement with Keio University School of Medicine to apply HGF therapy for spinal cord injury. |
| 2021-08 |
Initiated a Phase I/II clinical trial targeting neurotrophic keratitis by Clarus BioTherapeutics Inc. in the United States. |
| 2021-09 |
The international nonproprietary name for recombinant human HGF protein (KP-100) was designated as 'Oremepermin Alfa'. |
| 2021-09 |
The international non‑proprietary name for recombinant human HGF protein (KP‑100) was decided as 'Oremepermin Alfa'. |
| 2021-12 |
Registered a European patent for 'HGF formulation suitable for treating neurological disorders'. |
| 2022-03 |
Co-filed a patent with Keio University School of Medicine on treatment for chronic spinal cord injury. |
| 2022-09 |
Co-filed a patent with Keio University School of Medicine on combined HGF and iPS cell therapy for spinal cord injury. |
| 2022-11 |
Initiated a Phase III trial of HGF protein in patients with vocal fold scarring in Japan. |
| 2023-09 |
Started collaboration with Clarus Biotherapeutics in the U.S. to improve efficiency and scale of recombinant human HGF protein production. |
| 2023-10 |
Completed the final observation day of the Phase III clinical trial targeting acute spinal cord injury. |
| 2024-02 |
Released preliminary results of the Phase III clinical trial for acute spinal cord injury. |
| 2024-05 |
The Japanese generic name for HGF was decided as 'Oremepelin Alpha'. |
| 2024-05 |
The Japanese generic name for HGF was decided as 'Oremepelin Alpha'. |
| 2025-04 |
Opened the Nakanoshima Qross office. |
| 2025-06 |
Recombinant human HGF protein targeting acute spinal cord injury obtained orphan drug designation in the U.S. |
| 2025-10 |
Developed a general business action plan. |
| 2025-11 |
米国子会社（Kringle Pharma USA, Inc.）設立 |
